Biotechnology Company (NASDAQ: TECH) is rated “Medium Purchase” by analysts.

technology


Market Tech Ratings reports that Biotech Tech’s shares (NASDAQ: TECH – Get Rating) have been rated “average buy” by seven brokers covering the company. One analyst reviewed the stock with a sales comment and the four gave buying advice to the company. The average 12-month stock price for last year was $ 504.17.

Several analysts have recently commented on TECH shares. Wells Fargo and company Bio Tech have reduced the company’s price from $ 400.00 to $ 370.00 from “Equal Weight” to “Weight Loss” on Monday, April 25, according to a study. StockNews.com launches bio-tech coverage on Thursday, March 31st. They rated the company “Buy”. Robert W. Bard lowered its price target for Bio Tech from $ 520.00 to $ 500.00 in a study note on Thursday, May 5th. Finally, KiCorup lowered its price target for biotech from $ 600.00 to $ 500.00 in a study on Thursday, May 5th.

Another biotech news director, John El Higgins, sold 1,000 shares of the company on Tuesday, June 7. The stock traded at an average of $ 364.31, with a total trading volume of $ 364,310.00. Following the completion of the transaction, the Director currently owns 4,606 shares of the company, valued at approximately $ 1,678,011.86. The transaction is described in the SEC legal file on this hyperlink. Chief Executive Officer Charles R. Kummet also sold 5,104 shares of the company on Tuesday, June 7. The shares traded at an average of $ 365.00, with a total trading volume of $ 1,862,960.00. Following the completion of the transaction, the CEO now owns 198,338 shares of the company, valued at $ 72,393,370. A description of this sale can be found here. 4.10% of the stock is currently owned by insiders.

Many institutional investors have recently increased or decreased their shares in TECH. Tcwp LLC acquires a new position in bio-tech stocks for around $ 25,000. Confluence Wealth Services Inc. It acquired a new position of $ 33,000 in the 4th quarter on bio-tech stocks. Castleview Partners LLC acquired a new position in biotech stocks for about $ 36,000 in the fourth quarter. Aaron Wealth Advisors LLC acquired a new position in biotech stocks for about $ 42,000 in the first quarter. Finally, Ellevest Inc. In the first quarter, biotech stocks increased by 56.5 percent. Elevest Inc. acquired an additional 39 shares and acquired 108 shares of $ 47,000 worth of $ 47,000 last year. Institutional investors own 94.36 percent of the company.

NASDAQ: TECH shares opened at $ 353.18 on Friday. The market capitalization of the stock is $ 13.86 billion, the P / E ratio is 64.45, the P / E / G ratio is 1.91 and the Beta is 1.24. Bio Tech has a 1-year low of $ 318.07 and a 1-year high of $ 543.85. The company’s current ratio is 3.56, fast 2.79 and debt equity ratio 0.14. The 50-day moving average is $ 359.11 and the two-day moving average is $ 401.63.

Biotech (NASDAQ: Tech – Rating) last released its quarterly earnings data on Wednesday, May 4. The biotechnology company reported revenue of $ 1.96 in the first quarter, and the consensus estimate increased to $ 1.75 from $ 0.21. The company earned $ 290.40 million in the quarter, compared to $ 279.27 million expected by analysts. Bio Tech had a return of 16.82% and a net margin of 20.95%. The company’s quarterly revenue increased by 19.2 percent compared to the same period last year. During the same period last year, the business posted $ 1.61 EPS. As a group, stock analysts predict that Bio Tech will post 7.1 EPS for the current year.

The company recently announced its quarterly profit margin on Friday, May 27th. Investors registered on Monday, May 16 were given a $ 0.32 dividend. The first day of this distribution was Friday, May 13. This represents a $ 1.28 annual dividend and a profit margin of 0.36 percent. Biotech’s profit margin is currently 23.36 percent.

Profile of Bio Technical Company (Rate)

Biotech Corporation Corporation, along with its subsidiaries, develops, manufactures and sells life sciences rigs, equipment and services, as well as the diagnostic and biopsy processing markets worldwide. The company operates in two areas: protein science and diagnostics and genomics. The Department of Protective Sciences provides biological regimens for use in a variety of life sciences, research, and cell and genetic therapies, such as cytokines and growth factors, antibodies, small molecules, tissue culture, and cell selection technologies.

watch out

Expert Recommendations for Bio Tech (NASDAQ: TECH)

This instant news alert was created to provide fast and accurate reporting to readers with narrative science technology and MarketBeat financial information. This article was reviewed by the MarketBeat editorial team before it was published. Please send any questions or comments about this story to contact@marketbeat.com.

Do you need to invest $ 1,000 in biotechnology now?

Before you consider biotech, you want to hear this.

MarketBeat tracks Wall Street’s top rated and best-performing research analysts and the shares they recommend to their clients on a daily basis. MarketBeat has identified five stocks that senior whispers whispers to their customers to buy before the big market.

While Bio Techne currently has a “middle buy” rating among analysts, top rated analysts believe these five stocks are the best buy.

See 5 stocks here



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *